Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia By Ogkologos - March 26, 2026 137 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RECITE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... February 6, 2023 ESMO 2024 Press Conference September 13, 2024 Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... February 10, 2025 Why the Bone Marrow Registry Needs More Diverse Donors and How... March 30, 2021 Load more HOT NEWS News digest – skin cancer deaths, Public Health England plans and... Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... Scientists reveal how air pollution can cause lung cancer in people... Enhancements to NCI’s SEER Program Creating New Research Opportunities
